Table 2.
Patient and tumor characteristics of 276 metastatic renal cell carcinoma patients being treated with first‐line IO + IO/IO + TKI and C‐reactive protein data available to be stratified according to CRP kinetics defined by Ishihara et al.
| N | Overall, N = 276 | Non‐normalised, N = 79 (29%) | Normal, N = 141 (51%) | Normalised, N = 56 (20%) | P‐value | |
|---|---|---|---|---|---|---|
| Age at treatment initiation [years], Median (IQR) | 276 | 67 (60, 73) | 66 (60, 72) | 67 (60, 73) | 66 (58, 74) | > 0.9 |
| Male gender, n (%) | 192 (70%) | 54 (68%) | 100 (71%) | 38 (68%) | ||
| ECOG, n (%) | 266 | 0.3 | ||||
| 0 | 111 (42%) | 34 (45%) | 56 (41%) | 21 (39%) | ||
| 1 | 130 (49%) | 35 (46%) | 70 (51%) | 25 (46%) | ||
| 2 | 18 (6.8%) | 4 (5.3%) | 7 (5.1%) | 7 (13%) | ||
| 3 | 6 (2.3%) | 3 (3.9%) | 3 (2.2%) | 0 (0%) | ||
| 4 | 1 (0.4%) | 0 (0%) | 0 (0%) | 1 (1.9%) | ||
| IMDC, n (%) | 275 | < 0.001 | ||||
| Favorable | 54 (20%) | 8 (10%) | 42 (30%) | 4 (7.1%) | ||
| Intermediate | 160 (58%) | 45 (57%) | 83 (59%) | 32 (57%) | ||
| Poor | 61 (22%) | 26 (33%) | 15 (11%) | 20 (36%) | ||
| Combined* T‐stage, n (%) | 240 | 0.14 | ||||
| T1 | 60 (25%) | 10 (15%) | 38 (30%) | 12 (26%) | ||
| T2 | 26 (11%) | 7 (10%) | 17 (13%) | 2 (4.3%) | ||
| T3 | 108 (45%) | 28 (42%) | 57 (45%) | 23 (49%) | ||
| T4 | 26 (11%) | 14 (21%) | 7 (5.6%) | 5 (11%) | ||
| Tx | 20 (8.3%) | 8 (12%) | 7 (5.6%) | 5 (11%) | ||
| Combined* N‐Stage, n (%) | 230 | 0.8 | ||||
| N0 | 105 (46%) | 28 (45%) | 59 (47%) | 18 (42%) | ||
| N1 | 69 (30%) | 19 (31%) | 34 (27%) | 16 (37%) | ||
| Nx | 56 (24%) | 15 (24%) | 32 (26%) | 9 (21%) | ||
| M‐Stage, n (%) | 271 | 0.002 | ||||
| M0 | 85 (31%) | 16 (21%) | 51 (36%) | 18 (33%) | ||
| M1 | 164 (61%) | 58 (76%) | 71 (51%) | 35 (64%) | ||
| Mx | 22 (8.1%) | 2 (2.6%) | 18 (13%) | 2 (3.6%) | ||
| Nephrectomy, n (%) | 254 | 152 (60%) | 33 (50%) | 91 (68%) | 28 (51%) | 0.013 |
| Radiotherapy, n (%) | 236 | 104 (44%) | 31 (46%) | 52 (41%) | 21 (50%) | 0.6 |
| Clear‐cell histology, n (%) | 220 (83%) | 58 (76%) | 124 (91%) | 38 (72%) | 0.03 | |
| Grade histology, n (%) | 210 | 0.063 | ||||
| 1 | 14 (6.7%) | 4 (8.7%) | 9 (7.3%) | 1 (2.5%) | ||
| 2 | 89 (42%) | 17 (37%) | 58 (47%) | 14 (35%) | ||
| 3 | 79 (38%) | 16 (35%) | 48 (39%) | 15 (38%) | ||
| 4 | 28 (13%) | 9 (20%) | 9 (7.3%) | 10 (25%) | ||
| Systemic treatment combination, n (%) | 272 | 0.13 | ||||
| IO‐IO | 108 (40%) | 37 (48%) | 54 (39%) | 17 (31%) | ||
| IO‐TKI | 164 (60%) | 40 (52%) | 86 (61%) | 38 (69%) | ||
| Baseline CRP [mg L−1], Median (IQR) | 276 | 9 (2, 41) | 55 (26, 101) | 2 (1, 5) | 33 (20, 56) | < 0.001 |
| Duration for 1 month CRP [days], Median (IQR) | 238 | 21 (14, 23) | 20 (7, 25) | 21 (17, 22) | 21 (14, 24) | 0.3 |
| Time to therapy [months], Median (IQR) | 276 | 5 (1, 33) | 2 (0, 10) | 11 (2, 53) | 3 (0, 17) | < 0.001 |
| Maximum target lesion at 1st staging [%], Median (IQR) | 123 | −16 (−38, 15) | −19 (−34, 11) | −11 (−36, 20) | −32 (−48, −8) | 0.2 |
All values are median (Interquartile range) or frequencies (%).
ECOG, Eastern Cooperative Oncology Group; IMDC, International metastatic RCC database consortium; IO, Immunotherapy; IQR, Interquartile range; TKI, Tyrosine kinase inhibitor.